Boswellic Acids Improve Clinical Cognitive Scores and Reduce Systemic Inflammation in Patients With Mild to Moderate Alzheimer's Disease Publisher Pubmed



Karima S¹ ; Aghamollaii V² ; Mahmoodi Baram S³ ; Balenci L⁴ ; Lanctot KL⁵ ; Kiss A⁶ ; Tafakhori A⁷ ; Mahdavi M¹ ; Rajaei S³ ; Shateri S¹ ; Yarhoseini A² ; Mokhtari F³ ; Fotouhi A⁸ ; Riazi A⁴
Source: Journal of Alzheimer's Disease Published:2023

Abstract

Background: Recent therapeutic approaches for Alzheimer's disease (AD) have had limited success. Considering the association of neuroinflammation with AD symptoms as demonstrated in multiple studies, assessment of the clinical efficacy of molecules that reduce systemic or brain inflammation is warranted. Objective: This clinical trial assessed whether boswellic acids can improve cognitive and neuropsychiatric symptoms while reducing inflammation in AD patients. Methods: A double-blind, placebo-controlled, study was conducted on 85 AD patients randomized to boswellic acids (K-Vie™ as the main ingredient in Memowell™) or placebo for 6 months. Clinical Dementia Rating-Sum of Boxes (CDR-SOB) and Mini-Mental State Examination (MMSE) scores were compared to baseline and between groups and constituted the co-primary clinical efficacy endpoints. Secondary outcomes included neuropsychiatric assessment (Neuropsychiatric Inventory-Questionnaire, NPI-Q) and assessment of AD and inflammation biomarkers. Results: Patients on K-Vie™ showed a 3.1- and 1.6-unit improvement in MMSE and CDR-SOB scores, respectively, when compared to patients on placebo. NPI-Q analysis revealed significant improvement in the K-Vie™ but not in the placebo group. Only mild gastrointestinal side effects were reported in a few patients. Patients on K-Vie™ showed improvement in plasma AD biomarkers and reduction of key inflammatory cytokines including IL-6 and TNF. Conclusion: Our results support the positive cognitive effects of boswellic acids by reducing the systemic inflammation. © 2023 - IOS Press. All rights reserved.